Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Johnson & Johnson (JNJ) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $27.29, down 0.58% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 earnings with EPS of $0.18 beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07B in 2025 with net income of $391M, showing significant margin expansion from 2022 losses to 36.5% profit margin. Recent European Commission approval for Daybue in Rett syndrome expands market reach.

The stock presents a compelling value opportunity with a P/E of 12.24 below industry averages, supported by 70% analyst buy ratings and a $33.83 consensus target implying 24% upside. Key risks include Q1 2026 earnings miss volatility and high EV/EBITDA of 38.82. Institutional buying from BlackRock ($22.5M) and Alyeska Investment signals confidence in the growth trajectory despite technical bearish indicators.

Johnson & Johnson (JNJ) trades at $269.99, down slightly by 0.09% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth projected to reach $97.9B in 2026. Recent institutional activity shows mixed sentiment, with Nykredit A/S taking a new $235.82 million position while some firms reduced stakes. The stock faces headwinds from Stelara's patent expiration but benefits from new drug launches and a robust pharmaceutical pipeline.

JNJ presents a balanced outlook with analyst consensus favoring a Buy rating (52.5%) and a $286.93 price target, suggesting 6% upside. Key opportunities include double-digit growth potential and a 64-year dividend growth track record. Risks include patent cliffs, talc litigation liabilities, and MedTech sector challenges. The stock remains a defensive play with strong fundamentals but requires monitoring of pipeline execution and legal developments.